Alison Blenkinsopp

Alison Blenkinsopp

Auto-generated profile, based on publicly available information

Alison Blenkinsopp

School of Pharmacy, University of Bradford, Bradford, UK

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2006 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
ABA. Blenkinsopp
A. Blenkinsopp
PWP. Wilkie
P. Wilkie
MWM. Wang
M. Wang
PRP. A. Routledge
P. A. Routledge

1 February 2007 in Health Technology Assessment
Verified
Journal Article
Open access
PDF file
DRD Raynor
D Raynor
ABA Blenkinsopp
A Blenkinsopp
PKP Knapp
P Knapp
JGJ Grime
J Grime
DND Nicolson
D Nicolson
PSP Spoor
P Spoor
Health Technology Assessment Volume: 11, Issue: 5, Published in February 2007

5 September 2012 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
ABAlison Blenkinsopp
Alison Blenkinsopp
CBChristine Bond
Christine Bond
DRDavid K. Raynor
David K. Raynor

9 March 1996 in BMJ
Verified
Journal Article
Closed access
ABAlison Blenkinsopp
Alison Blenkinsopp
CBColin Bradley
Colin Bradley
Self medication with over the counter medicines has long been a feature of the lay health system. With the reclassification of certain drugs, the public can buy preparations that were previously available only on prescription. Sales of over the counter medicines are now equivalent to a third of the NHS drugs bill; governments throughout the world see self medication as a way of shifting some of the cost of health care onto consumers. The trend towards increased self care and with it the increasing empowerment of patients has many potential benefits; collaboration between doctors and pharmacists will be critical. Over any two week period, nine out of 10 adults will report having experienced at least one ailment.1 2 Non-prescription medicines, commonly known as over the counter or OTC medicines, are used to treat one in four of these episodes.2 Sales of over the counter medicines in pharmacy and grocery outlets reached pounds sterling1268.5 million in 1994 (box 1)—about a third of the NHS drugs bill of pounds sterling3.6 billion. ### Box 1 Market breakdown for major categories of non-prescription medicines3 View this table: In the late 1980s the government fuelled the over the counter market by making it easier to reclassify certain medicines from prescription only status to allow over the counter sale in pharmacies. Progress was slow at first, with 11 medicines being reclassified between 1983 and 1992 (table 1), but since 1992 a further 40 medicines have been reclassified. This widened range of non-prescription medicines has highlighted the role of pharmacists, to whom the public is increasingly looking for advice. View this table: Table 1 Medicines deregulated from prescription only to pharmacy status, 1980-95 Factors promoting and inhibiting the reclassification of drugs are shown in box 2. The deregulation is occurring against a background of pressure on the primary care drugs bill. Self care and self medication with non-prescription medicines are seen by governments throughout …

6 September 2004 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
DADarren M. Ashcroft
Darren M. Ashcroft
PQPaul Quinlan
Paul Quinlan
ABAlison Blenkinsopp
Alison Blenkinsopp

20 October 2006 in BMJ
Verified
Journal Article
Closed access
PDF file
EHElaine M Hay
Elaine M Hay
NFNadine E Foster
Nadine E Foster
ETElaine Thomas
Elaine Thomas
GPGeorge Peat
George Peat
MPMike Phelan
Mike Phelan
JSJulius Sim
Julius Sim
Objectives To evaluate the effectiveness of two primary care strategies for delivering evidence based care to people aged 55 or over with knee pain: enhanced pharmacy review and community physiotherapy. Design Pragmatic multicentre randomised clinical trial. Setting 15 general practices in North Staffordshire. Participants 325 adults aged 55 years or over (mean 68 years) consulting with knee pain; 297 (91%) reached six month follow-up. Interventions Enhanced pharmacy review (pharmacological management in accordance with an algorithm); community physiotherapy (advice about activity and pacing and an individualised exercise programme); control (advice leaflet reinforced by telephone call). Main outcome measure Change in Western Ontario and McMaster Universities osteoarthritis index (WOMAC) at 3, 6, and 12 months. Results Mean baseline WOMAC pain score was 9.1 (SD 3.7), and mean baseline function score was 29.9 (SD 12.8). At three months, the mean reductions in pain scores were 0.41 (SD 2.8) for control, 1.59 (3.2) for pharmacy, and 1.56 (3.4) for physiotherapy; reductions in function scores were 0.80 (8.5), 2.61 (9.8), and 4.79 (10.8). Compared with control, mean differences in change scores for physiotherapy were 1.15 (95% confidence interval 0.2 to 2.1) for pain and 3.99 (1.2 to 6.8) for function; those for pharmacy were 1.18 (0.3 to 2.1) for pain and 1.80 (−0.8 to 4.5) for function. These differences were not sustained to six or 12 months. Significantly fewer participants in the physiotherapy group reported consulting their general practitioner for knee pain in the follow-up period, and use of non-steroidal anti-inflammatory drugs was lower in the physiotherapy and pharmacy groups than in the control group. Conclusions Evidence based care for older adults with knee pain, delivered by primary care physiotherapists and pharmacists, resulted in short term improvements in health outcomes, reduced use of non-steroidal anti-inflammatory drugs, and high patient satisfaction. Physiotherapy seemed to produce a shift in consultation behaviour away from the traditional general practitioner led model of care. Trial registration UK National Research Register N0286046917; Current Controlled Trials ISRCTN55376150.